Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases.
Expert Panel on Radiation Oncology-Brain Metastases; Lo SS, Gore EM, Bradley JD, Buatti JM, Germano I, Ghafoori AP, Henderson MA, Murad GJ, Patchell RA, Patel SH, Robbins JR, Robins HI, Vassil AD, Wippold FJ 2nd, Yunes MJ, Videtic GM. Expert Panel on Radiation Oncology-Brain Metastases, et al. Among authors: robbins jr. J Palliat Med. 2014 Aug;17(8):880-6. doi: 10.1089/jpm.2014.9417. Epub 2014 Jun 27. J Palliat Med. 2014. PMID: 24971478 Free PMC article. Review.
ACR Appropriateness Criteria® follow-up and retreatment of brain metastases.
Patel SH, Robbins JR, Gore EM, Bradley JD, Gaspar LE, Germano I, Ghafoori P, Henderson MA, Lutz ST, McDermott MW, Patchell RA, Robins HI, Vassil AD, Wippold FJ 2nd, Videtic GM; Expert Panel on Radiation Oncology–Brain Metastases. Patel SH, et al. Among authors: robbins jr. Am J Clin Oncol. 2012 Jun;35(3):302-6. doi: 10.1097/COC.0b013e31824be246. Am J Clin Oncol. 2012. PMID: 22609733 Review.
Getting Cheeky With It: Adult Rhabdomyosarcoma.
Morrison CM, Robbins JR. Morrison CM, et al. Among authors: robbins jr. Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):12. doi: 10.1016/j.ijrobp.2024.10.015. Int J Radiat Oncol Biol Phys. 2025. PMID: 39674602 No abstract available.
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.
Mell LK, Torres-Saavedra PA, Wong SJ, Kish JA, Chang SS, Jordan RC, Liu T, Truong MT, Winquist EW, Takiar V, Wise-Draper T, Robbins JR, Rodriguez CP, Awan MJ, Beadle BM, Henson C, Narayan S, Spencer SA, Powell S, Dunlap N, Sacco AG, Hu KS, Park HS, Bauman JE, Harris J, Yom SS, Le QT. Mell LK, et al. Among authors: robbins jr. Lancet Oncol. 2024 Dec;25(12):1576-1588. doi: 10.1016/S1470-2045(24)00507-2. Epub 2024 Nov 14. Lancet Oncol. 2024. PMID: 39551064 Free article. Clinical Trial.
Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.
Juloori A, Katipally RR, Lemons JM, Singh AK, Iyer R, Robbins JR, George B, Hall WA, Pitroda SP, Arif F, Fung J, Pillai A, Liao CY, Sharma M, Liauw SL. Juloori A, et al. Among authors: robbins jr. Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):202-213. doi: 10.1016/j.ijrobp.2022.09.052. Epub 2022 Sep 13. Int J Radiat Oncol Biol Phys. 2023. PMID: 36108891 Clinical Trial.
90 results